91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Rare autoimmune diseases can increase patients’ vulnerability to infection and often require tailored considerations for vaccination. Read the article to learn what makes these cases distinct and what to factor in when designing a vaccine schedule.
-
Rare disease N of 1 studies offer patients the hope of finding a personalised, effective treatment. 91黑料 experts discuss the challenges, solutions and promise of these unique trials in this PharmaTimes article.
-
91黑料’s Dr Neena Nizar and Dr Jana Benesh discuss the ways effective engagement with PAOs is shaping rare disease research and contributing to better therapeutic outcomes. Read the article in IPI for insights into patient engagement in preclinical, clinical and post-approval phases of development.
-
With more than 170 early stage IPF clinical programs, IPF is one of the most dy?namic rare diseases spaces for development.
-
Rare diseases can disproportionately affect minorities, yet these communities are often underrepresented in clinical studies. 91黑料’s experts suggest ways to improve engagement and diversity.
-
Advantages and disadvantages of using historical controls, and how data can be analysed using Bayesian statistics to develop a ‘predictive understanding’ of a drug.
-
In this article, 91黑料 experts Kirsten Sherman Cervati and William C. Maier discuss strategies to make and their families.
-
In this article, Patricia Murphy discusses how the industry needs to make rare disease clinical trials more human.
-
In this article, Laura Iliescu, director of patient advocacy strategy at 91黑料 Plc, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
-
This article describes some of the systemic factors that produce barriers at various stages of the rare disease drug development process, as well as identifies strategies to improve diversity in these trials
